Two birds, one trial

Novo Nordisk A/S is developing diabetes drug Victoza liraglutide for obesity and is hopeful that its fully enrolled cardiovascular outcomes trial in diabetics will be enough to allay any concerns about the potential CV risk of the GLP-1 analog in obese patients while also meeting postmarketing requirements for diabetes.